六月 2026
nurixtx.com
显示 Similarweb 估计数据。
关联 GA4,公开验证您的网站指标
与您的成功同步
绑定 Google Analytics,验证您网站的流量及用户参与度指标
跳出率
44.38%
每次访问页数
2.00
平均访问时长
00:01:21
nurixtx.com的 10 大竞争对手
在 六月 2026 与 nurixtx.com 相似的前 10 名网站,按关键字流量、受众定位和市场重叠方面与 nurixtx.com 的关联性排名
Aragen Life Sciences offers reliable commercial API manufacturing services, ensuring high-quality production and scalability for pharmaceutical and biotech industries.
跳出率
41.22%
每次访问页数
1.98
平均访问时长
00:00:53
相似度评分
95%Announcements, Financial Reports & Filings SEC Filings Reports
跳出率
40.13%
每次访问页数
1.87
平均访问时长
00:00:23
相似度评分
93%Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines. Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and […]
跳出率
53.89%
每次访问页数
1.70
平均访问时长
00:00:04
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income.…
跳出率
57.62%
每次访问页数
1.51
平均访问时长
00:00:21
跳出率
35.27%
每次访问页数
1.97
平均访问时长
00:00:18
Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway.
- 公司
- Celcuity
- 行业
- 不适用
跳出率
45.71%
每次访问页数
1.96
平均访问时长
00:00:38
Careers - Septerna
跳出率
53.57%
每次访问页数
1.67
平均访问时长
00:00:39
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that provides next-level therapies to elevate care.
- 公司
- - -
- 行业
- - -
跳出率
40.64%
每次访问页数
2.58
平均访问时长
00:01:29
Explore the challenges patients face after FDA approval of treatments like DUVYZAT for Duchenne muscular dystrophy. Stephanie Trafton, Head of US Value & Access at ITF Therapeutics, discusses navigating insurance hurdles, available resources for securing access, and the supportive community dedicated to helping families overcome barriers to treatment. Discover vital support options and empowering insights to ensure you get the care you need.
- 行业
- 不适用
跳出率
70.49%
每次访问页数
1.36
平均访问时长
00:00:20
nurixtx.com在 六月 2026 的前五名竞争对手是:cullgen.com、aragen.com、smmttx.com、preludetx.com等。
根据 Similarweb 的月访问量数据,nurixtx.com 在 六月 2026 的头号竞争对手是 cullgen.com。与 nurixtx.com 相似度排名第二的网站是 aragen.com,排名第三的是 smmttx.com。
在 六月 2026,preludetx.com 被评为与 nurixtx.com 相似度第四高的网站,fortressbiotech.com 位居第五。
进入前十名榜单的其他五家竞争对手分别是 halozyme.com、celcuity.com、septerna.com、moonlaketx.com 和 itftherapeutics.com。
